Dose-escalation study of SAR439859, an oral selective estrogen receptor degrader, in postmenopausal women with estrogen receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer

首页> 外文期刊>Intelligence: A Multidisciplinary Journal >Dose-escalation study of SAR439859, an oral selective estrogen receptor degrader, in postmenopausal women with estrogen receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer

【24h】

Dose-escalation study of SAR439859, an oral selective estrogen receptor degrader, in postmenopausal women with estrogen receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer

机译：雌激素受体阳性和人表皮生长因子受体2阴性转移性乳腺癌的绝经后妇女的口服选择性雌激素受体降解剂量升级研究。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal》 |2020年第2020期|共3页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学;
关键词
入库时间 2022-08-20 01:55:48

相似文献

外文文献
中文文献
专利

1. Dose-escalation study of SAR439859, an oral selective estrogen receptor degrader, in postmenopausal women with estrogen receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：雌激素受体阳性和人表皮生长因子受体2阴性转移性乳腺癌的绝经后妇女的口服选择性雌激素受体降解剂量升级研究。
2. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. [J] . Ingrid A Mayer, Vandana G Abramson, Steven J Isakoff, Journal of Clinical Oncology . 2014,第12期

机译：用雌激素受体阳性/人表皮生长因子受体2阴性转移性乳腺癌的甲基磷酸肌乙酸乙酰膦酸-3-激酶抑制剂Buparlisib的癌症期IB研究。
3. Randomized Phase 2 Neoadjuvant Trial Evaluating Anastrozole and Fulvestrant Efficacy for Postmenopausal, Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Patients: Results of the UNICANCER CARMINA 02 French Trial (UCBG 0609) [J] . Lerebours Florence, Rivera Sofia, Mouret-Reynier Marie-Ange, Cancer: A Journal of the American Cancer Society . 2016,第19期

机译：评估阿那曲唑和氟来芬特对绝经后，雌激素受体阳性，人表皮生长因子受体2-阴性乳腺癌患者的疗效的随机2期新辅助试验：UNICANCER CARMINA 02法国试验（UCBG 0609）
4. Estrogen Receptor-Positive Breast Cancer: Traditional Prognostics, Molecular Pathology: A New Breast Cancer Taxonomy and 21st Century Personalized Prognostic and Predictive Assays [C] . Frederick L. Baehner International Symposium on Cancer Metastasis and the Lymphovascular system: Basis for Rational Therapy . 2009

机译：雌激素受体阳性乳腺癌：传统预测，分子病理：新的乳腺癌分类和21世纪个性化预测和预测测定
5. Selective utilization of ectopic epidermal growth factor receptor signaling in estrogen receptor positive breast cancer cells. [D] . Miller, David Lee. 1996

机译：雌激素受体阳性乳腺癌细胞中异位表皮生长因子受体信号的选择性利用。
6. Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer [O] . Ingrid A. Mayer, Vandana G. Abramson, Steven J. Isakoff, -1

机译：在雌激素受体阳性/人表皮生长因子受体2阴性转移性乳腺癌中接受泛磷酰胺3-激酶抑制剂布帕利西普与来曲唑的癌症Ib期研究
7. Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer [O] . Ingrid A. Mayer, Vandana G. Abramson, Steven J. Isakoff, 2014

机译：用雌激素受体阳性/人表皮生长因子受体2阴性转移性乳腺癌的甲吡唑与苯并唑氏菌癌癌IB研究

Dose-escalation study of SAR439859, an oral selective estrogen receptor degrader, in postmenopausal women with estrogen receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer

著录项

相似文献

相关主题

期刊订阅